Vesicare (Solifenacin succinate)
Canadian Meds |
Policy | Legal
Terms | Meds Index
Vesicare is a modern medical product for the treatment of the overactive bladder syndrome. This drug is also used for the treatment of the imperative urinary incontinence and imperative vesical tenesmus.
The active component of this drug is Solifenacin which provides cholinolytic and spasmolytic pharmacological action which is characterized by the reduction of the smooth muscle tone of the urinary tracts. It inhibits muscarine receptors which are responsible for the muscle contraction and at the same time regulate the tone of the area of the smooth muscles which are responsible for the function of the urinary tracts.
The maximal pharmacological effect occurs in 4 weeks of the drug use, and this has been proved in the clinical studies in men and women with the overactive bladder syndrome. The efficiency of therapy is kept within 12 months, and this provides the prolong comfort at the chronic enuresis.
Before starting the use of Vesicare it is necessary to consult your attending physician and find out a cause of the frequent urination. If there are no other reasons of the frequent urination in the patient (for example, heart failure or kidney disease), a health care provider will indicate the course of the treatment and dosage according to the clinical image of the patient.
The tablets of Vesicare are prescribed orally with plenty of liquid regardless of the meals. The initial dose is 5 mg once a day. In case this dose is not effective, it may be increased by two times up to 10 mg once a day.
Senior patients do not need the adjustment of the dose. However, in case of the simultaneous use of the drugs which are strong inhibitors of CYP3A4 enzyme (ritonavir, nelfinavir, ketoconazole, itraconazole) the maximal daily dose must not exceed 5 mg.
- Vesicare is not recommended for the use by patients with individual intolerance of the drug ingredients in particular the active ingredient Solifenacin
- Patients with retention of urine, severe gastrointestinal diseases, closed-angle glaucoma, severe renal or hepatic failure, or hereditary intolerance of galactose must refuse from the treatment with the help of this drug
- Vesicare must be prescribed with caution during pregnancy and if possible it is better to refuse from the use of this drug
- There are no data about the release of Solifenacin with breast milk. That is why the use of this drug is not recommended in the period of the breast-feeding,
© 2003-2017 Rx Meds Canada . All Rights Reserved